
Sign up to save your podcasts
Or
The January 2024 replay starts the new year off with four previously posted episodes on dementia. The episode begins with an interview with Dr. Kenneth Langa on the prevalence of dementia and mild cognitive impairment in the US. The episode continues with an interview with Dr. Beau Ances about the burden amyloid has on individuals with Down syndrome compared to autosomal dominant Alzheimer disease. The next interview is with Dr. Erik Musiek on the use of lecanemab in early Alzheimer disease. The fourth and final interview is with Dr. Vijay Ramanan on the eligibility for anti-amyloid treatment.
Related Podcast Links:
Estimating the Prevalence of Dementia and Mild Cognitive Impairment in the United States: https://directory.libsyn.com/episode/index/id/25811241
Comparison of Amyloid Burden in Individuals with Down Syndrome Versus Autosomal Dominant Alzheimer Disease: https://directory.libsyn.com/episode/index/id/25881414
Lecanemab in Early Alzheimer Disease: https://directory.libsyn.com/episode/index/id/25428333
Eligibility for Anti-Amyloid Treatment: https://directory.libsyn.com/episode/index/id/28300052
Related Article Links:
Estimating the Prevalence of Dementia and Mild Cognitive Impairment in the US: https://jamanetwork.com/journals/jamaneurology/article-abstract/2797274?resultClick=1
Comparison of Amyloid Burden in Individuals with Down Syndrome Versus Autosomal Dominant Alzheimer's Disease: A Cross-Sectional Study: https://www.thelancet.com/journals/laneur/article/PIIS1474-4422(22)00408-2/fulltext
Eligibility for Anti-Amyloid Treatment in a Population-Based Study of Cognitive Aging: https://www.neurology.org/doi/10.1212/WNL.0000000000207770
Disclosures can be found at Neurology.org
4.7
279279 ratings
The January 2024 replay starts the new year off with four previously posted episodes on dementia. The episode begins with an interview with Dr. Kenneth Langa on the prevalence of dementia and mild cognitive impairment in the US. The episode continues with an interview with Dr. Beau Ances about the burden amyloid has on individuals with Down syndrome compared to autosomal dominant Alzheimer disease. The next interview is with Dr. Erik Musiek on the use of lecanemab in early Alzheimer disease. The fourth and final interview is with Dr. Vijay Ramanan on the eligibility for anti-amyloid treatment.
Related Podcast Links:
Estimating the Prevalence of Dementia and Mild Cognitive Impairment in the United States: https://directory.libsyn.com/episode/index/id/25811241
Comparison of Amyloid Burden in Individuals with Down Syndrome Versus Autosomal Dominant Alzheimer Disease: https://directory.libsyn.com/episode/index/id/25881414
Lecanemab in Early Alzheimer Disease: https://directory.libsyn.com/episode/index/id/25428333
Eligibility for Anti-Amyloid Treatment: https://directory.libsyn.com/episode/index/id/28300052
Related Article Links:
Estimating the Prevalence of Dementia and Mild Cognitive Impairment in the US: https://jamanetwork.com/journals/jamaneurology/article-abstract/2797274?resultClick=1
Comparison of Amyloid Burden in Individuals with Down Syndrome Versus Autosomal Dominant Alzheimer's Disease: A Cross-Sectional Study: https://www.thelancet.com/journals/laneur/article/PIIS1474-4422(22)00408-2/fulltext
Eligibility for Anti-Amyloid Treatment in a Population-Based Study of Cognitive Aging: https://www.neurology.org/doi/10.1212/WNL.0000000000207770
Disclosures can be found at Neurology.org
135 Listeners
315 Listeners
47 Listeners
496 Listeners
3,321 Listeners
90 Listeners
1,109 Listeners
24 Listeners
194 Listeners
517 Listeners
132 Listeners
350 Listeners
182 Listeners
366 Listeners
78 Listeners